Delivery Order SPE2DB20D1109-SPE2DB25FP83M
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,717.95 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen auto-injectors on September 25, 2025, with an ultimate completion date of October 17, 2025. This firm fixed price, competitively awarded contract—placed with no set-aside designation—represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,343.59 on July 22, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitively awarded, firm fixed-price contract is not set aside for any socioeconomic category and is scheduled for completion by August 12, 2025. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Tezspire is a specialty biologic medication used in the treatment...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a $14,061.54 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. The contract, which is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), carries an ultimate completion date of September 3, 2025, and involves no set-aside designation....
- The Defense Logistics Agency awarded a $2,343.59 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen auto-injectors, with an ultimate completion date of September 3, 2025. This is a non-set-aside competitive award issued on August 12, 2025, with performance conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Tezspire 210 mg/1.91 ml pen auto-injectors. This firm fixed-price delivery order, valued at $4,687.18, carries an ultimate completion date of August 21, 2025, and represents a non-competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for Tezspire 210 mg/1.91 mL pen auto-injectors valued at $4,687.18, with completion scheduled for August 8, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was awarded through open competition. The contract is to be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- The Defense Logistics Agency awarded a $2,343.59 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL auto-injector pens on August 13, 2025, with completion expected by September 4, 2025. This delivery order represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and active through December 2026. The award involved no set-aside designation and...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Tezspire 210 mg/1.91 mL auto-injector pens. This competitively awarded, non-set-aside contract carries a ceiling value of $7,030.77 with a firm fixed price structure and is scheduled for completion by September 19, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Tezspire is a biologic...
- The Defense Logistics Agency awarded a $11,717.95 delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen auto-injectors. This firm fixed-price, competitively awarded contract has an ultimate completion date of September 10, 2025, and will be performed at the company's corporate office in Conshohocken, Pennsylvania. Tezspire is a biologic medication used to treat moderate-to-severe asthma, representing the type of specialized pharmaceutical product critical to military...
- The Defense Logistics Agency awarded a delivery order valued at $7,030.77 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. The contract is non-competitive, firm fixed price delivery order with an ultimate completion date of September 8, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under a larger Indefinite Delivery Contract vehicle with the...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP83MDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $18,748.72 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen auto-injectors, with an ultimate completion date of October 17, 2025. This competitive, firm fixed-price delivery order was issued under a non-set-aside procurement and performed at the vendor's corporate office in Conshohocken, Pennsylvania. Tezspire is a biologic medication used in the treatment of moderate-to-severe asthma, representing the type of specialized pharmaceutical products that AmerisourceBergen regularly supplies through its federal medical procurement contracts. This delivery order represents a child contract flowing from AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves critical roles in the Defense Health Agency's medical supply chain, providing brand-name and generic medications, specialty treatments, vaccines, and medical devices to military and veteran healthcare systems worldwide. The company's competitively awarded federal contracts demonstrate its capability to meet rigorous federal procurement requirements across a diverse portfolio of pharmaceutical and medical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.7k | 9/25/25 |